201 related articles for article (PubMed ID: 27544796)
1. NF-κB dysregulation in multiple myeloma.
Matthews GM; de Matos Simoes R; Dhimolea E; Sheffer M; Gandolfi S; Dashevsky O; Sorrell JD; Mitsiades CS
Semin Cancer Biol; 2016 Aug; 39():68-76. PubMed ID: 27544796
[TBL] [Abstract][Full Text] [Related]
2. A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
Mark C; Warrick J; Callander NS; Hematti P; Miyamoto S
Mol Cancer Res; 2022 Sep; 20(9):1456-1466. PubMed ID: 35604822
[TBL] [Abstract][Full Text] [Related]
3. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):16-34. PubMed ID: 23534949
[TBL] [Abstract][Full Text] [Related]
4. Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
Yan W; Li R; He J; Du J; Hou J
Cell Signal; 2015 Apr; 27(4):851-9. PubMed ID: 25643631
[TBL] [Abstract][Full Text] [Related]
5. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.
Vrábel D; Pour L; Ševčíková S
Blood Rev; 2019 Mar; 34():56-66. PubMed ID: 30501907
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.
Huynh M; Pak C; Markovina S; Callander NS; Chng KS; Wuerzberger-Davis SM; Bakshi DD; Kink JA; Hematti P; Hope C; Asimakopoulos F; Rui L; Miyamoto S
J Biol Chem; 2018 Feb; 293(7):2452-2465. PubMed ID: 29279332
[TBL] [Abstract][Full Text] [Related]
7. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.
Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H
Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322
[TBL] [Abstract][Full Text] [Related]
8. [Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].
Wang H; Liu X; Xu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):531-7. PubMed ID: 18549623
[TBL] [Abstract][Full Text] [Related]
9. The kinase NIK as a therapeutic target in multiple myeloma.
Gardam S; Beyaert R
Expert Opin Ther Targets; 2011 Feb; 15(2):207-18. PubMed ID: 21204728
[TBL] [Abstract][Full Text] [Related]
10. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
11. PSMB4 promotes multiple myeloma cell growth by activating NF-κB-miR-21 signaling.
Zheng P; Guo H; Li G; Han S; Luo F; Liu Y
Biochem Biophys Res Commun; 2015 Mar; 458(2):328-33. PubMed ID: 25656574
[TBL] [Abstract][Full Text] [Related]
12. Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro.
Qin Y; Sun CY; Lu FR; Shu XR; Yang D; Chen L; She XM; Gregg NM; Guo T; Hu Y
Leuk Res; 2012 Apr; 36(4):514-20. PubMed ID: 22226224
[TBL] [Abstract][Full Text] [Related]
13. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma: lusting for NF-kappaB.
Gilmore TD
Cancer Cell; 2007 Aug; 12(2):95-7. PubMed ID: 17692798
[TBL] [Abstract][Full Text] [Related]
15. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.
Conticello C; Giuffrida R; Adamo L; Anastasi G; Martinetti D; Salomone E; Colarossi C; Amato G; Gorgone A; Romano A; Iannolo G; De Maria R; Giustolisi R; Gulisano M; Di Raimondo F
Leuk Res; 2011 Jan; 35(1):52-60. PubMed ID: 20674018
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation.
Bariana M; Cassella E; Rateshwar J; Ouk S; Liou HC; Heller C; Colorado I; Feinman R; Makhdoom A; Siegel DS; Heller G; Tuckett A; Mondello P; Zakrzewski JL
Mol Cancer Ther; 2022 Dec; 21(12):1798-1809. PubMed ID: 36190955
[TBL] [Abstract][Full Text] [Related]
17. Role of NF-κB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells.
Cippitelli M; Stabile H; Kosta A; Petillo S; Lucantonio L; Gismondi A; Santoni A; Fionda C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768145
[TBL] [Abstract][Full Text] [Related]
18. 1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo.
Ito K; Nakazato T; Xian MJ; Yamada T; Hozumi N; Murakami A; Ohigashi H; Ikeda Y; Kizaki M
Cancer Res; 2005 May; 65(10):4417-24. PubMed ID: 15899834
[TBL] [Abstract][Full Text] [Related]
19. Andrographolide inhibits multiple myeloma cells by inhibiting the TLR4/NF-κB signaling pathway.
Gao H; Wang J
Mol Med Rep; 2016 Feb; 13(2):1827-32. PubMed ID: 26707811
[TBL] [Abstract][Full Text] [Related]
20. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
Zhao Y; Zhang K; Li G; Zhang X; Shi D
PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
